Invokana Lawsuit Details

2610_the_kidneyWhen a drug or family of drugs cause a specific serious side effect or serious injury that is not warned against by its manufacturers, we will typically see mass tort lawyers take notice. What usually follows are television advertisements.

Many law firms have created television commercials, advising patients of a developing litigation concerning the type 2 diabetes drug Invokana.

Invokana is considered a “SGLT2 inhibitor.” Sanctioned for the treatment of diabetes type 2, SGLT2 inhibitors have been related to a potentially dangerous medical conditions such as diabetic ketoacidosis and kidney failure.

On May 15, 2015 the US Food & Drug Administration declared that SGLT2 inhibitors, a whole new class of diabetes medications that prevent kidney function, can result in “ketoacidosis”, an ailment in which the entire body produces abnormally high amounts of the blood acid. If left untreated, ketoacidosis can result in diabetic coma and death.

The federal agency warned patients that are presently taking Invokana and Farxiga, in conjunction with drugs with the same mechanism of action to look for warning signs of ketoacidosis. Those warming signs may include: Disorientation or confusion

  • Extreme fatigue and drowsiness
  • Disorientation or confusion
  • Nausea and vomiting
  • Abdominal pain
  • Difficulty breathing

INVOKANA and its class of drugs are designed to inhibit renal glucose reabsorption together with the aim of reducing blood glucose levels. As a result, around 60% of glucose is not being metabolized, but instead is expelled through the kidneys of a population of consumers already susceptible to kidney disease; leading to increased stress on several INVOKANA consumers’ kidneys.

Since INVOKANA prevents someone from using a substantial volume of the body’s primary fuel, glucose, INVOKANA customers must consider an alternate fuel source, fat. As the body starts to break down fat for fuel, acids are known as ketones are introduced into your blood stream, creating the opportunity of acidosis (which is increased acidity in the blood).

With 2015 sales of $1.4 billion, INVOKANA is among Janssen’s blockbuster drugs though has only been on the market for a couple of years.

INVOKANA’s 2015 sales statistics represent a 124% increase in the previous year’s sales. INVOKANA’s terrific sales figures are caused by considerable marketing efforts that are made to consumers and also the medical community.

According to certain data, INVOKANA consumers are at an increased and unreasonable risk of developing ketoacidosis, and very serious kidney injuries, including renal failure.

In general, when an individual is being affected by ketoacidosis (excess ketones), they also report high blood-glucose levels, and frequent urination.

Usually, your body excretes excess ketones through urination so as to obtain proper blood-acid balance; however, because INVOKANA already places the kidneys under duress by forcing significant quantities of unmetabolized glucose over the urinary tract as a common strategy to managing diabetes type 2, INVOKANA users often cannot obtain blood-acid balance with the normal process, urination, and sometimes require medical intervention to avoid the acidosis from becoming deadly.

Under normal circumstances, an individual relies on the emergency jettison of excess glucose and ketones to help keep blood-acid balance through frequent urination only once in dire need.

Thus, INVOKANA’s mechanism to treat high blood glucose, expelling unmetabolized glucose via the urinary tract, which leads to more frequent urination, is a process the body reserves for elevated glucose or acidosis emergencies.

INVOKANA forces this emergency process on its consumers in the usual course of treatment- daily. Ketoacidosis is uncommon for type 2 diabetics, but far more common in type 1 diabetics.

Type 1 diabetics have a greater chance of suffering from ketoacidosis because, like most INVOKANA consumers, their bodies can’t metabolize glucose for fuel, leaving a substantial quantity to become expelled through the kidneys and the urinary tract, compelling one’s body to use fat for fuel.

Ketoacidosis can cause organ failure, including renal failure, in case it isn’t treated speedily.

Since INVOKANA’s introduction to U.S. consumers, the FDA has seen a substantial volume of reports of diabetic ketoacidosis and kidney injuries, including renal failure from users of INVOKANA.

Based in part on the total number of lawsuits brought by injured victims of Invokana, the Judicial Panel of Multi District Litigation or “JPML”, has ordered that all the pending Invokana lawsuits be sent to the District Court of New Jersey for coordination.

For more information, please visit www.fightforvictims.com or call 800-430-6191.

This entry was posted in Defective Drugs. Bookmark the permalink.